JNJ · News · 20261014N
MedTech Market Weakness
JOHNSON & JOHNSON · 2026-10-14 · Importance 49 · Surprise 32 · No source text
Johnson & Johnson’s MedTech sales increased 2.5% to $8.64 billion in the third quarter of 2026, below internal expectations. Weakness was concentrated in international markets and at Abiomed, indicating softer procedure or device demand outside the United States and continued execution challenges in the heart-support business. The performance contrasts with 7.7% growth in Innovative Medicine and represents a material market-demand issue for the MedTech segment.
Key facts
- MedTech sales increased 2.5% to $8.64 billion in Q3 2026. source
- Management said MedTech's performance fell below internal expectations, particularly in international markets and at Abiomed. source
- Johnson & Johnson acknowledged continued weakness in parts of the MedTech business on its third-quarter 2026 earnings call. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +0.8% | MedTech sales increased 2.5% to $8.64 billion in Q3 2026. |